glp1 receptor

GLP-1 receptor agonist 3 is a GLP-1 receptor agonist,Example 4A-1, has EC50s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively.

TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.

Semaglutide TFA is a glucagon-like peptide-1 congener that induces weight loss, lowers blood glucose levels, and reduces cardiovascular risk in diabetic patients.Semaglutide TFA induces mild-to-moderate and transient gastrointestinal disturbances, and may be used in the study of type 2 diabetes and obesity.

TT-OAD2 is a non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor (EC50: 5 nM), with potential for diabetes treatment.

Orforglipron (LY3502970) belongs to non-peptide small molecule GLP-1 receptor agonists and is a highly selective, orally effective GLP-1 receptor agonist with good cell permeability and oral bioavailability. This compound is used in research on type 2 diabetes and obesity, demonstrating significant glucose-lowering and weight-reducing activities.

Semaglutide is a long-acting, selective, competitive GLP-1R agonist and a long-acting analog of human glucagon-like peptide-1, exhibiting potent hypoglycemic, weight-loss, cardioprotective, and neuroprotective effects. Upon activation of the GLP-1R, semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, while also enhancing autophagy and suppressing oxidative stress and apoptosis. Semaglutide also plays a role in regulating mitochondrial function and lipid metabolism. Semaglutide is being investigated for use in type 2 diabetes, obesity, Parkinson’s disease, metabolic and fatty liver diseases (MASLD), and other neurodegenerative and liver diseases, as well as in cancer research.

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

Retatrutide is a triple receptor agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), with FDA approval for the indication of obesity.Retatrutide may be used in studies of obesity, type 2 diabetes, and non-alcoholic steatohepatitis.

Tirzepatide (LY3298176) Acetate (2023788-19-2 free base) is a new molecule that can control blood glucose levels by combining dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[3]

Avexitide (Exendin-3(9-39)amide) is a specific, competitive GLP-1 receptor antagonist (Ki = 0.36 nM). Avexitide binds to the GLP-1 receptor (GLP-1R) with high affinity (Kd = 0.42 nM), blocking the interaction between endogenous GLP-1 and the receptor, thereby counteracting the effects of excessive GLP-1 secretion. Avexitide is being studied for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism.

1H-Benzimidazole-6-carboxylic acid is a GLP-1 receptor agonist.

GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of 64.5 nM, and is utilized in diabetes treatment research.

GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

MK 0893 is a potent and selective Glucagon Receptor (GR) antagonist (IC50=6.6 nM) with competitive, reversible, high binding affinity and functional cAMP activity, which attenuates glucagon induced blood glucose elevation and reduces ambient glucose levels in acute and chronic mouse models.

GLP-1R Antagonist 1 is an orally active, CNS penetrant and non-competitive glucagon-like peptide 1 receptor (GLP-1R) antagonist (IC50: 650 nM).

VU0453379 is a highly selective, central nervous system-penetrant, positive allosteric modulator of glucagon-like peptide-1R (EC50: 1.3 μM).

CT-996 is an orally active GLP-1 receptor agonist that exhibits preferential cAMP signaling and reduces endocytosis. Oral administration of CT-996 improves glycemic control and reduces body weight and body fat.

GLP-1 secretion by human enteroendocrine NCI-H716 cells is augmented in a dose-dependent manner by the addition of CPE.

Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity.

Tirzepatide sodium is the sodium salt form of a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist peptide drug that enhances insulin secretion and improves glycemic control by simultaneously activating GIP and GLP-1 receptors. In research and clinical settings, Tirzepatide sodium has also demonstrated effects in reducing body weight and improving metabolic parameters, and is used in studies related to type 2 diabetes and metabolic disorders.

GLP-1 receptoragonist 16 (Example 53) is a GLP-1 agonist applicable for research in diabetes, obesity, or diseases related to non-alcoholic steatohepatitis.

GLP-1 receptor agonist 15 (Example 4) is a GLP receptor agonist with an EC50 of 0.74 nM. It exhibits an IC50 of 10.1 μM against the hERG potassium ion channel. This compound is applicable for research in the diabetes field.

GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterated form of GLP-1R agonist 17, which acts as a GLP-1 receptor agonist and is applicable in cardiovascular and metabolic disease research.

GLP-1 receptor agonist 7 (Compound 130b) is a potent agonist of the Glucagon-like peptide-1 (GLP-1) receptor. It exhibits high affinity for GLP-1R, effectively triggering the generation of intracellular cAMP via G-protein-mediated signaling with an EC50 of ≤ 0.2 nM. As a potent incretin mimetic, this compound modulates glucose homeostasis by enhancing insulin secretion in a glucose-dependent manner. It serves as a significant molecular tool for studying the therapeutic interventions for type 2 diabetes, obesity, and other GLP-1R-related metabolic disorders